AIMS: Uridine diphosphate-glucuronosyltransferase 2B (UGT2B) enzymes conjugate testosterone metabolites to enable their excretion in humans. The functional significance of the UGT2B genetic variants has never been described in humans. We evaluated UGT2B variants in relation to plasma androstane-3α,17β-diol-glucuronide (AAG) levels and the prostate cancer risk. RESULTS: AAG levels were measured in sera from 150 controls and compared to the polymorphisms of UGT2B17, UGT2B15, and UGT2B7. Genomic DNA from controls (301) and cases (148) was genotyped for the polymorphisms, and odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using unconditional logistic regression analyses. Having two copies of UGT2B17 was associated with higher AAG levels in controls among Whites (p=0.02), but not Blacks (p=0.82). Logistic regression models adjusting for age and race revealed that homozygosity for the G allele of the UGT2B15(D85Y) polymorphism was directly associated with the prostate cancer risk (OR=2.70, 95% CI=1.28, 5.55). CONCLUSIONS: While the small sample size limits inference, our findings suggest that an association between the UGT2B17 copy number variant (CNV) and serum AAG levels in Whites, but unexpectedly not in Blacks. This novel observation suggests that genetic determinants of AAG levels in Blacks are unrelated to the UGT2B17 CNV. This study replicates the results that show an association of UGT215(D85Y) with an increased prostate cancer risk.
AIMS: Uridine diphosphate-glucuronosyltransferase 2B (UGT2B) enzymes conjugate testosterone metabolites to enable their excretion in humans. The functional significance of the UGT2B genetic variants has never been described in humans. We evaluated UGT2B variants in relation to plasma androstane-3α,17β-diol-glucuronide (AAG) levels and the prostate cancer risk. RESULTS:AAG levels were measured in sera from 150 controls and compared to the polymorphisms of UGT2B17, UGT2B15, and UGT2B7. Genomic DNA from controls (301) and cases (148) was genotyped for the polymorphisms, and odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using unconditional logistic regression analyses. Having two copies of UGT2B17 was associated with higher AAG levels in controls among Whites (p=0.02), but not Blacks (p=0.82). Logistic regression models adjusting for age and race revealed that homozygosity for the G allele of the UGT2B15(D85Y) polymorphism was directly associated with the prostate cancer risk (OR=2.70, 95% CI=1.28, 5.55). CONCLUSIONS: While the small sample size limits inference, our findings suggest that an association between the UGT2B17 copy number variant (CNV) and serum AAG levels in Whites, but unexpectedly not in Blacks. This novel observation suggests that genetic determinants of AAG levels in Blacks are unrelated to the UGT2B17 CNV. This study replicates the results that show an association of UGT215(D85Y) with an increased prostate cancer risk.
Authors: Jong Park; Lan Chen; Luke Ratnashinge; Thomas A Sellers; Jean-Paul Tanner; Ji-Hyun Lee; Nicole Dossett; Nicholas Lang; Fred F Kadlubar; Christine B Ambrosone; Babu Zachariah; Randy V Heysek; Stephen Patterson; Julio Pow-Sang Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-08 Impact factor: 4.254
Authors: Jong Y Park; Jean-Paul Tanner; Thomas A Sellers; Yifan Huang; Colleen K Stevens; Nicole Dossett; Ravi A Shankar; Babu Zachariah; Randy Heysek; Julio Pow-Sang Journal: Urology Date: 2007-08 Impact factor: 2.649
Authors: Willie Wilson; Fernando Pardo-Manuel de Villena; Beverly D Lyn-Cook; Pradeep K Chatterjee; Timothy A Bell; David A Detwiler; Rodney C Gilmore; Isis C Valladeras; Camille C Wright; David W Threadgill; Delores J Grant Journal: Genomics Date: 2004-10 Impact factor: 5.736
Authors: Jong Park; Lan Chen; Kristin Shade; Philip Lazarus; John Seigne; Stephen Patterson; Mohamed Helal; Julio Pow-Sang Journal: J Urol Date: 2004-06 Impact factor: 7.450
Authors: Sabine Rohrmann; William G Nelson; Nader Rifai; Norma Kanarek; Shehzad Basaria; Konstantinos K Tsilidis; Ellen Smit; Edward Giovannucci; Elizabeth A Platz Journal: Urology Date: 2007-04 Impact factor: 2.649
Authors: Julie M Cunningham; Scott J Hebbring; Shannon K McDonnell; Mine S Cicek; G Bryce Christensen; Liang Wang; Steven J Jacobsen; James R Cerhan; Michael L Blute; Daniel J Schaid; Stephen N Thibodeau Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-05 Impact factor: 4.254
Authors: Dominique Scherer; Lisel M Koepl; Elizabeth M Poole; Yesilda Balavarca; Liren Xiao; John A Baron; Li Hsu; Anna E Coghill; Peter T Campbell; Sarah E Kleinstein; Jane C Figueiredo; Johanna W Lampe; Katharina Buck; John D Potter; Richard J Kulmacz; Mark A Jenkins; John L Hopper; Aung K Win; Polly A Newcomb; Cornelia M Ulrich; Karen W Makar Journal: Genes Chromosomes Cancer Date: 2014-03-28 Impact factor: 5.006
Authors: Sandra M Lopez; Alexander I Agoulnik; Manqi Zhang; Leif E Peterson; Egla Suarez; Gregory A Gandarillas; Anna Frolov; Rile Li; Kimal Rajapakshe; Christian Coarfa; Michael M Ittmann; Nancy L Weigel; Irina U Agoulnik Journal: Clin Cancer Res Date: 2016-03-11 Impact factor: 12.531
Authors: Delores J Grant; Ani Manichaikul; Anthony J Alberg; Elisa V Bandera; Jill Barnholtz-Sloan; Melissa Bondy; Michele L Cote; Ellen Funkhouser; Patricia G Moorman; Lauren C Peres; Edward S Peters; Ann G Schwartz; Paul D Terry; Xin-Qun Wang; Temitope O Keku; Cathrine Hoyo; Andrew Berchuck; Dale P Sandler; Jack A Taylor; Katie M O'Brien; Digna R Velez Edwards; Todd L Edwards; Alicia Beeghly-Fadiel; Nicolas Wentzensen; Celeste Leigh Pearce; Anna H Wu; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Joseph H Rothstein; Francesmary Modugno; Roberta Ness; Kirsten Moysich; Mary Anne Rossing; Jennifer A Doherty; Thomas A Sellers; Jennifer B Permuth-Way; Alvaro N Monteiro; Douglas A Levine; Veronica Wendy Setiawan; Christopher A Haiman; Loic LeMarchand; Lynne R Wilkens; Beth Y Karlan; Usha Menon; Susan Ramus; Simon Gayther; Aleksandra Gentry-Maharaj; Kathryn L Terry; Daniel W Cramer; Ellen L Goode; Melissa C Larson; Scott H Kaufmann; Rikki Cannioto; Kunle Odunsi; John L Etter; Ruea-Yea Huang; Marcus Q Bernardini; Alicia A Tone; Taymaa May; Marc T Goodman; Pamela J Thompson; Michael E Carney; Shelley S Tworoger; Elizabeth M Poole; Diether Lambrechts; Ignace Vergote; Adriaan Vanderstichele; Els Van Nieuwenhuysen; Hoda Anton-Culver; Argyrios Ziogas; James D Brenton; Line Bjorge; Helga B Salvensen; Lambertus A Kiemeney; Leon F A G Massuger; Tanja Pejovic; Amanda Bruegl; Melissa Moffitt; Linda Cook; Nhu D Le; Angela Brooks-Wilson; Linda E Kelemen; Paul D P Pharoah; Honglin Song; Ian Campbell; Diana Eccles; Anna DeFazio; Catherine J Kennedy; Joellen M Schildkraut Journal: Cancer Med Date: 2019-04-18 Impact factor: 4.711
Authors: Adriana C Vidal; Cocoa Tucker; Joellen M Schildkraut; Ricardo M Richardson; Megan McPhail; Stephen J Freedland; Cathrine Hoyo; Delores J Grant Journal: BMC Cancer Date: 2013-11-22 Impact factor: 4.430